Neurobehavioral Substrates of Proranolol's Effects on Drug Cue Reactivity
| Status: | Recruiting |
|---|---|
| Conditions: | Smoking Cessation |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 10/20/2018 |
| Start Date: | January 16, 2018 |
| End Date: | August 31, 2019 |
| Contact: | Bryana Roberts, BS |
| Email: | Bryana.Roberts@duke.edu |
| Phone: | 919-684-7601 |
The central objective of this project is to obtain proof-of-concept data demonstrating the
effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to
personal smoking environments and behavioral responses in a laboratory smoking behavior task.
Human cigarette smokers (N = 50) will take photographs of locations where they do and do not
smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg)
or placebo prior to completing: A) An MRI session assessing neural responses to personal
smoking/non-smoking environments, standard smoking/non-smoking environments and proximal
smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response
to environmental cues.
effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to
personal smoking environments and behavioral responses in a laboratory smoking behavior task.
Human cigarette smokers (N = 50) will take photographs of locations where they do and do not
smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg)
or placebo prior to completing: A) An MRI session assessing neural responses to personal
smoking/non-smoking environments, standard smoking/non-smoking environments and proximal
smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response
to environmental cues.
Inclusion Criteria:
- Generally healthy
- Right-handed
- Smoke an average of 5 or more cigarettes per day of a brand delivering at least 0.5 mg
nicotine
- Have been smoking regularly for at least 2 years, with a stable smoking pattern over
the past 6 months
- FTND score of 4 or greater at screening
- Afternoon expired CO concentration of at least 10 ppm or morning urinary cotinine >
100 ng/ml
Exclusion Criteria:
- Inability to attend all required sessions
- Significant health problems that would interfere with completion of study procedures
- MRI contraindications (e.g. pacemaker, metal implants)
- Presence of exclusionary psychopathology based on a structured clinical interview
(current alcohol/substance use disorder moderate or severe [mild is allowable], any
history of bipolar disorder or psychosis. Individuals in early remission from
substance use disorder (not in a controlled environment) may also be allowed at the
PI's discretion.
- Current use of psychoactive medications per self-report or urine screen. Certain
prescribed medications are allowable at the PI's discretion if appropriate
documentation is provided (e.g. copy of prescription or physician letter)
- Positive breath alcohol concentration
- Pregnant, breastfeeding or planning to become pregnant during the course of study
- Problems with vision that cannot be corrected with contacts or glasses
- Current regular use of smokeless tobacco, smoking cessation medications or other
non-combustible nicotine products
- Plans to alter smoking pattern (e.g. reduction, cessation) during the course of study
- Current use of beta adrenergic medication
- Systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg (sitting or
standing)
- Low resting heart rate (< 60 bpm)
- Abnormal EKG
- Presence of severe anemia
- Presence of electrolyte imbalance that impact blood pressure
- Presence of any other contraindications for propranolol (e.g. cardiovascular disease,
bronchial asthma, prior allergic reaction to propranolol)
We found this trial at
1
site
Durham, North Carolina 27710
Principal Investigator: Jason A Oliver, PhD
Phone: 919-684-7601
Click here to add this to my saved trials
